Kidney replacement therapy and mortality in metformin-associated lactic acidosis with acute kidney injury (2015-2021): a multi-year cohort study

二甲双胍相关乳酸性酸中毒合并急性肾损伤患者的肾脏替代治疗与死亡率(2015-2021年):一项多年队列研究

阅读:1

Abstract

Metformin-associated lactic acidosis (MALA) is a life-threatening complication. Treatment of MALA includes supportive care and dialysis. However, the role of kidney replacement therapy (KRT) in MALA is controversial, this study aimed to compare patient and kidney outcomes between MALA-acute kidney injury (AKI) patients receiving KRT (KRT group) vs. supportive care (supportive care group). A cohort study was conducted on 143 adult patients with MALA-AKI from 1 January 2015 to 31 December 2021. The primary outcome was the patient mortality rate and predictive factors of mortality, while the secondary outcomes were kidney survival. The overall mortality rate in our MALA-AKI cohort was 20.3% (29 of 143 patients). The KRT group had a lower mortality rate compared with the supportive care group (16% vs. 28.6%, P = 0.006). Among patients who received dialysis, hemodialysis (HD) was associated with a lower mortality rate compared with acute peritoneal dialysis (APD) (8.9% vs. 30.8%, P = 0.044). Patients who received late KRT (≥6 h) had a trend toward higher mortality compared with those who received early KRT (<6 h). Independent predictors of mortality were oliguria (HR 8.59, P = 0.002), prolonged prothrombin time (HR 1.20, P = 0.001) and higher Sequential Organ Failure Assessment (SOFA) scores (HR 1.26, P = 0.006). MALA-AKI was associated with high mortality, and KRT reduced mortality rate when compared with supportive care. HD was the most effective treatment in MALA-AKI, early KRT initiation (<6 h) showed a trend toward lower mortality and oliguria, prolonged prothrombin time, and higher SOFA scores were identified as prognostic markers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。